Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874912 | 0.87 | L3MBTL1 (0.44) | KMT2AMEN1GRIN2BNPC1RAB9A | |
| SCHEMBL4877598 | 0.85 | OPRD1 (0.41) | KMT2AMEN1GRIN2BALDH1A1 | |
| SCHEMBL4880349 | 0.85 | HDAC4 (0.46) | KMT2AMEN1GRIN2BALDH1A1SMN1; SMN2 | |
| SCHEMBL4878256 | 0.85 | ALDH1A1 (0.43) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL4877674 | 0.83 | MEN1 (0.41) | KMT2AMEN1CCR6GRIN2BNPC1 | |
| SCHEMBL4876705 | 0.82 | OPRD1 (0.46) | KMT2AMEN1GRIN2BALDH1A1SMN1; SMN2 | |
| SCHEMBL4880460 | 0.79 | ELOVL1 (0.43) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL4880538 | 0.79 | SOAT1 (0.50) | KMT2AMEN1MMP2MMP13ALDH1A1 | |
| SCHEMBL4880120 | 0.78 | KMT2A (0.41) | KMT2AMEN1MMP1MMP2ALDH1A1 | |
| SCHEMBL4883883 | 0.77 | MMP1 (0.52) | MMP1MMP13ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | KMT2A 1132/4885MEN1 3740/4885CCR6 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.